相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
G. Frasci et al.
ANNALS OF ONCOLOGY (2009)
Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment
H. -G. Moon et al.
ANNALS OF ONCOLOGY (2009)
Survival among women with triple receptor-negative breast cancer and brain metastases
S. Dawood et al.
ANNALS OF ONCOLOGY (2009)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
B. Corkery et al.
ANNALS OF ONCOLOGY (2009)
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
S. R. Young et al.
BMC CANCER (2009)
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Sharon Nofech-Mozes et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The epidemiology of triple-negative breast cancer, including race
Katrina F. Trivers et al.
CANCER CAUSES & CONTROL (2009)
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Jessica M. Dolle et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Emad A. Rakha et al.
CLINICAL CANCER RESEARCH (2009)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
Ji Eun Uhm et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel
Ewan K. A. Millar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Mieke Kriege et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F] Fluorodeoxyglucose
Joerg Schwarz-Dose et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Can Women With Early-Stage Breast Cancer Make an Informed Decision for Mastectomy?
E. Dale Collins et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Eloisi Caldas-Lopes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
Takayoshi Uematsu et al.
RADIOLOGY (2009)
Triple-negative breast cancers are increased in black women regardless of age or body mass index
Lesley A. Stead et al.
BREAST CANCER RESEARCH (2009)
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Marilyn L. Kwan et al.
BREAST CANCER RESEARCH (2009)
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy:: results of WSG AM-01 trial
O. Gluz et al.
ANNALS OF ONCOLOGY (2008)
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2008)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Impact of triple negative phenotype on breast cancer prognosis
Henry G. Kaplan et al.
BREAST JOURNAL (2008)
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype
David Sarrió et al.
CANCER RESEARCH (2008)
Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2008)
How basal are triple-negative breast cancers?
Francois Bertucci et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy
Paul L. Nguyen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group
Marianne Kyndi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
Ittai Ben-Porath et al.
NATURE GENETICS (2008)
Weekly paclitaxel in the adjuvant treatment of breast cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Epidemiology of basal-like breast cancer
Robert C. Millikan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer
J. Tommiska et al.
ONCOGENE (2008)
MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer
Y. Eralp et al.
ANNALS OF ONCOLOGY (2008)
αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer
Olga Ivanov et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
David S. P. Tan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women
Wei-Tse Yang et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
Rosalba Torrisi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
The CD44(+)/CD24(-) phenotype is enriched in basal-like breast tumors
Gabriella Honeth et al.
BREAST CANCER RESEARCH (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Integrated profiling of basal and luminal breast cancers
Jose Adelaide et al.
CANCER RESEARCH (2007)
Value and use of economic evaluation in oncology - Reply
Mark N. Levine
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hormonal markers in breast cancer: Coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study
Xiaohong R. Yang et al.
CANCER RESEARCH (2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study
Christiane K. Kuhl et al.
LANCET (2007)
Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status
Andrew G. Glass et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Marc Tischkowitz et al.
BMC CANCER (2007)
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2007)
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
Chee-Onn Leong et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
Differences in risk factors for breast cancer molecular subtypes in a population-based study
Xiaohong R. Yang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
BRCA1 dysfunction in sporadic basal-like breast cancer
N. C. Turner et al.
ONCOGENE (2007)
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy
Raihanatou Diallo-Danebrock et al.
CLINICAL CANCER RESEARCH (2007)
Triple-negative breast cancer: therapeutic options
Susan Cleator et al.
LANCET ONCOLOGY (2007)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
Bruce G. Haffty et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: Association between caveolin-1 expression and ABI-007
Kadri Altundag et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
Anna Bergamaschi et al.
GENES CHROMOSOMES & CANCER (2006)
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer
Socorro Maria Rodriguez Pinilla et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
S. Banerjee et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
L. G. Fulford et al.
HISTOPATHOLOGY (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance
C. Chabalier et al.
CELL CYCLE (2006)
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas
SM Rodríguez-Pinilla et al.
CLINICAL CANCER RESEARCH (2006)
Generation of a functional mammary gland from a single stem cell
M Shackleton et al.
NATURE (2006)
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
Lyndsay N. Harris et al.
BREAST CANCER RESEARCH (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Typical medullary breast carcinomas have a basal/myoepithelial phenotype
J Jacquemier et al.
JOURNAL OF PATHOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
DM Abd El-Rehim et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
SR Lakhani et al.
CLINICAL CANCER RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors
K Collett et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
WD Foulkes et al.
CANCER RESEARCH (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Cell-type-specific responses to chemotherapeutics in breast cancer
MA Troester et al.
CANCER RESEARCH (2004)
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3
PM Gilmore et al.
CANCER RESEARCH (2004)
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers
ZGC Wang et al.
CANCER RESEARCH (2004)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
KN Ogston et al.
BREAST (2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis
E Korsching et al.
LABORATORY INVESTIGATION (2002)
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer
PO Chapppuis et al.
JOURNAL OF MEDICAL GENETICS (2002)
The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
SR Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases
H Tsuda et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2000)
分享论文
